86 search results for screening
Webinars for Patients
) Myeloproliferative Neoplasms (MPN) (2024) Breast Cancer Screening (2024) Advanced and Metastatic Bladder
https://www.nccn.org/patientresources/patient-resources/patient-webinarsPermission to Cite or Use NCCN Content
Cancer Screening and Diagnosis Cancer in People with HIV Cancer-Associated Venous Thromboembolic, Colorectal Cancer Screening Dermatofibrosarcoma Protuberans Distress Management Esophageal, Lung Cancer Screening Management of Immunotherapy-Related Toxicities Melanoma: Cutaneous, Cancer Risk Reduction Breast Cancer Screening and Diagnosis Cancer in People with HIV Cancer, Leukemia Colon Cancer Colorectal Cancer Screening Dermatofibrosarcoma Protuberans Distress
https://www.nccn.org/guidelines/permission-to-cite-or-use-nccn-contentDecember 2022 Summit Report
Purpose of the Summit Patients with cancer often have widely divergent care experiences from screening through survivorship. Differences in care delivery and outcomes may be due, in part, to varying patient preferences, patient needs according to varying intersectional identities, barriers to accessing appropriate and affirming cancer screening and treatment. A landscape, Continuum from Screening through Survivorship Tuesday, December 5, 2023 For More Information: https
https://www.nccn.org/docs/default-source/oncology-policy-program/december-2022-summit-report.pdf?sfvrsn=94daf5e7_12023 Summit Report
Patient Advocacy Summit Navigating the Care Continuum from Screening through Survivorship Summary Report Tuesday, December 5, 2023 8:30 AM – 3:30 PM Presented at The National Press Club in Washington, DC and Virtually © 2024 National Comprehensive Cancer Network, Inc. All rights, to thoughtfully discuss issues associated with care transitions, including from screening to diagnosis, Appendix 1. NCCN Patient Advocacy Summit: Navigating the Care Continuum from Screening through
https://www.nccn.org/docs/default-source/oncology-policy-program/2023-summit-report.pdf?sfvrsn=9db11db7_2Imaging AUC Compendium
include: Indications Screening Diagnosis Purpose Frequency Staging Treatment response assessment
https://www.nccn.org/compendia-templates/compendia/imaging-appropriate-use-criteria-nccn-imaging-aucHIT
Breast Cancer Screening and Diagnosis Colorectal Cancer Screening Genetic/Familial High-Risk, : Colorectal, Endometrial, and Gastric Lung Cancer Screening Prostate Cancer Early Detection, Breast Cancer - Invasive Breast Cancer Breast Cancer - Metastatic Breast Cancer Breast Cancer Screening, Cancer Colorectal Cancer Screening Cutaneous B-Cell Lymphomas Cutaneous T-Cell Lymphomas Diffuse, Cancer Screening Mantle Cell Lymphoma Marginal Zone Lymphomas Melanoma Mesothelioma: Pleural
https://www.nccn.org/redirects/hitTreatment by Cancer Type
, & Risk Reduction Breast Cancer Screening and Diagnosis Version: 2022 Colorectal Cancer Screening, Lung Cancer Screening Version: 2023
https://www.nccn.org/patientresources/patient-resources/guidelines-for-patients/treatment-by-cancer-typeDetection, Prevention, and Risk Reduction
, & Risk Reduction Breast Cancer Screening and Diagnosis Version: 2022 Colorectal Cancer Screening, Lung Cancer Screening Version: 2023
https://www.nccn.org/patientresources/patient-resources/guidelines-for-patients/detection-prevention-and-risk-reductionSupportive Care
, & Risk Reduction Breast Cancer Screening and Diagnosis Version: 2022 Colorectal Cancer Screening, Lung Cancer Screening Version: 2023
https://www.nccn.org/patientresources/patient-resources/guidelines-for-patients/supportive-careSpecific Populations
, & Risk Reduction Breast Cancer Screening and Diagnosis Version: 2022 Colorectal Cancer Screening, Lung Cancer Screening Version: 2023
https://www.nccn.org/patientresources/patient-resources/guidelines-for-patients/specific-populationsSubmission Request Form
Screening and Diagnosis - 2.2025 Cancer in People with HIV - 1.2025 Cancer-Associated Venous, Lymphoma - 3.2025 Chronic Myeloid Leukemia - 3.2025 Colon Cancer - 3.2025 Colorectal Cancer Screening, Kaposi Sarcoma - 2.2025 Kidney Cancer - 3.2025 Lung Cancer Screening - 1.2025 Management
https://www.nccn.org/guidelines/submissions-request-to-the-guidelines-panels/submission-request-formHarmonized Guidelines
) - Guidelines for Detection, Prevention, & Risk Reduction Breast Cancer Screening and Diagnosis Version 2.2024 Colorectal Cancer Screening Version 3.2022 Prostate Cancer Early
https://www.nccn.org/global/what-we-do/harmonized-guidelinesAt a Glance
for the treatment of nearly every type of cancer, as well as key cancer screening and prevention topics, Imaging AUC™) include recommendations pertaining to cancer screening, diagnosis, staging, treatment
https://www.nccn.org/home/news/at-a-glance2021-State-Oncology-Society-Forum-Summary
Screening, Treatment, and Survivorship Laura Makaroff, DO, Senior Vice President, Prevention & Early, and subsequent public awareness campaign that endorsed the safe resumption of cancer screening and treatment, -related delays in cancer screening and treatment. Dr. Richardson discussed the CDC’s COVID-19 Home
https://www.nccn.org/docs/default-source/business-policy/2021-state-oncology-society-forum-summary.pdf?sfvrsn=1a14acee_2NCCN_Oncology_Research_Program_Brochure
research collaborations between NCCN Member Institutions and industry in cancer screening, of the first lung cancer screening program in Antelope Valley. This initiative has touched many
https://www.nccn.org/docs/default-source/oncology-research-program-(orp)/nccn_oncology_research_program_brochure.pdf?sfvrsn=ebab0181_3Imaging AUC Compendium Reviewer Acknowledgement
Cancer Institute at the University of Utah Lung Cancer Screening
https://www.nccn.org/compendia-templates/compendia/imaging-appropriate-use-criteria-nccn-imaging-auc/imaging-auc-compendium-reviewer-acknowledgementNCCN LGBTQ Health Equity Infographic
Asking patients about their preferences for treatment, pronouns, support system, etc. Asking patients about their fertility plans/wishes so they can be fully informed about treatment options available to them. Ensuring educational materials feature diverse representation. Receiving trauma-informed training for this specific population to reduce the likelihood of unintentionally retraumatizing patients during screening, examinations, etc. Providers Need to Create More Welcoming
https://www.nccn.org/docs/default-source/oncology-policy-program/nccn-lgbtq-health-equity-infographic.pdf?sfvrsn=c771d22d_1(Reconciliation) NCCN Holds Twelfth Annual State Oncology Society Forum 2023
to biomarker testing and screening, as well as various levels of prior-authorization reform, and fertility, Carolina, Oklahoma). Cori Chandler of ACS CAN focused on the importance of biomarker screening and testing
https://www.nccn.org/docs/default-source/oncology-policy-program/(reconciliation)-nccn-holds-twelfth-annual-state-oncology-society-forum-2023.pdf?sfvrsn=4d6f3dd0_1NCCN Guidance on Inclusive Language
. For example: “Men and anyone with a prostate should discuss prostate cancer screening, appropriate opioid prescribing and screening for Opioid Use Disorder (OUD) for reproductive age female
https://www.nccn.org/docs/default-source/about/nccn-guidance-on-inclusive-language.pdf?sfvrsn=53c8c78f_22021_Elevating_Cancer_Equity_Webinar_Slides
or meeting notes. Offers flexible hours for screening and treatment appointments. Offers culturally, . Supporting Access to Screening: Congress should allocate additional funding for CDC screening, ) and the Colorectal Cancer Control Program (CCCP). Congress should also allocate funds for screening that prioritizes cancers where disparities are particularly prevalent. Supporting Access to Screening, with screening, early detection and treatment support. Congress should restore funds for the National
https://www.nccn.org/docs/default-source/oncology-policy-program/2021_elevating_cancer_equity_webinar_slides.pdf?sfvrsn=e11f66e4_4